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Abstract
Background: Long non-coding RNAs (lncRNAs) play a fundamental role in colorectal cancer (CRC) development,
however, lncRNA expression profiles in CRC and its precancerous stages remain to be explored. We aimed to study
whole genomic lncRNA expression patterns in colorectal adenoma–carcinoma transition and to analyze the
underlying functional interactions of aberrantly expressed lncRNAs.
Methods: LncRNA expression levels of colonic biopsy samples (20 CRCs, 20 adenomas (Ad), 20 healthy controls (N))
were analyzed with Human Transcriptome Array (HTA) 2.0. Expression of a subset of candidates was verified by qRT-
PCR and in situ hybridization (ISH) analyses. Furthermore, in silico validation was performed on an independent HTA 2.0,
on HGU133Plus 2.0 array data and on the TCGA COAD dataset. MiRNA targets of lncRNAs were predicted with
miRCODE and lncBase v2 algorithms and miRNA expression was analyzed on miRNA3.0 Array data. MiRNA-mRNA
target prediction was performed using miRWALK and c-Met protein levels were analyzed by immunohistochemistry.
Comprehensive lncRNA-mRNA-miRNA co-expression pattern analysis was also performed.
Results: Based on our HTA results, a subset of literature-based CRC-associated lncRNAs showed remarkable expression
changes already in precancerous colonic lesions. In both Ad vs. normal and CRC vs. normal comparisons 16 lncRNAs,
including downregulated LINC02023, MEG8, AC092834.1, and upregulated CCAT1, CASC19 were identified showing
differential expression during early carcinogenesis that persisted until CRC formation (FDR-adjusted p < 0.05). The
intersection of CRC vs. N and CRC vs. Ad comparisons defines lncRNAs characteristic of malignancy in colonic tumors,
where significant downregulation of LINC01752 and overexpression of UCA1 and PCAT1 were found. Two candidates
with the greatest increase in expression in the adenoma-carcinoma transition were further confirmed by qRT-PCR
(UCA1, CCAT1) and by ISH (UCA1). In line with aberrant expression of certain lncRNAs in tumors, the expression of
miRNA and mRNA targets showed systematic alterations. For example, UCA1 upregulation in CRC samples occurred in
parallel with hsa-miR-1 downregulation, accompanied by c-Met target mRNA overexpression (p < 0.05).
Conclusion: The defined lncRNA sets may have a regulatory role in the colorectal adenoma-carcinoma transition.
A subset of CRC-associated lncRNAs showed significantly differential expression in precancerous samples, raising
the possibility of developing adenoma-specific markers for early detection of colonic lesions.
Keywords: Long non-coding RNA, lncRNA, Colorectal cancer, Colorectal adenoma, Human transcriptome Array
2.0, Microarray, qRT-PCR, UCA1, Immunohistochemistry, In situ hybridization
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Background
The incidence and mortality of colorectal cancer (CRC)
are continuously increasing with approximately 1.4 million
new CRC cases and 700.000 registered deaths worldwide
[1]. Therefore, identification of molecular markers of CRC
that might enhance the objective classification or the early
detection of the disease remains highly relevant, as CRC is
one of the most curable cancers if detected early [2]. Be-
sides the commonly investigated molecular markers, such
as DNA mutations, DNA methylation or mRNA expres-
sion alterations, interest is growing in an emerging novel
class of non-coding RNAs, long non-coding RNAs
(lncRNAs) [3–5].
LncRNAs are defined as transcripts longer than 200
base pairs without an open reading frame [6]. This class of
non-coding RNAs represents a diverse group with known
and predicted functions for gene expression regulation
[7–9]. According to experimental data, lncRNAs can
interact with DNA, RNA and also with proteins and can
either promote or inhibit transcription [10]. In contrast to
miRNA-mediated regulation, the function and mechanism
of action of certain lncRNAs can be diverse; lncRNAs are
involved in genomic imprinting, transcriptional regulation,
protein scaffolding, maintenance of hetero-euchromatin
balance, can function as a miRNA sponge, and also medi-
ate disease-derived alterations of mRNAs, miRNAs and
proteins [9, 11]. Dysregulated lncRNAs are known to con-
tribute to CRC formation through the disruption of vari-
ous signaling cascades including Wnt/β-catenin, EGFR/
IGF-IR (KRAS and PI3K pathways), TGF-β, p53 and Akt
signaling pathways, and also via influencing the epithelial-
mesenchymal transition program [12]. To date, 172.216
human lncRNA transcripts have been identified according
to NONCODEv5 database [13] and their number con-
tinues to increase. Recent studies have demonstrated that
several lncRNAs have a key regulatory role in various dis-
eases including CRC [14]. During the carcinogenesis,
lncRNA expression alterations affect major biological pro-
cesses, and therefore. lncRNAs are considered as powerful
molecular markers and also potential therapeutic targets
in various cancers [3, 15].
In the present study, we aimed to determine the differ-
entially expressed lncRNAs at the whole genome level
focusing on the colorectal adenoma-carcinoma transi-
tion to identify lncRNAs showing specific alterations
only in CRC tissue and common lncRNA patterns char-
acteristic both in benign and malignant colonic neo-
plasms. Furthermore, we validated the lncRNA
expression alterations by qRT-PCR, in situ hybridization,
on an independent HTA 2.0 dataset, HGU133 Plus2.0,
and The Cancer Genome Atlas (TCGA) Colon adeno-
carcinoma (COAD) datasets. We also report an associ-
ation between the dysregulated lncRNAs and mRNA,
miRNA and protein expression.
Methods
Sample collection
During routine screening endoscopy examinations bi-
opsy samples were collected from patients with un-
treated colorectal cancer (n = 20; Astler-Coller modified
Dukes B-D), with colorectal adenomas (n = 20; tubulo-
villous: n = 9, tubular: n = 11; with low-grade dysplasia:
n = 18, with high-grade dysplasia: n = 2), and from
healthy donors (n = 20). Healthy donors had been re-
ferred to the outpatient clinic with constipation, rectal
bleeding or chronic abdominal pain. Ileocolonoscopy
showed normal macroscopic appearance, and no abnor-
mal histologic changes were detected in biopsy samples.
None of the healthy patients had familial history of
CRC. Biopsies were immediately put in RNALater
stabilization reagent (Qiagen GmbH, Hilden, Germany)
and stored at − 80 °C. Written informed consent was
provided by all patients. The study was approved by the
local ethics committee (Semmelweis University Re-
gional and Institutional Committee of Science and Re-
search Ethics; Nr.: ETT TUKEB 23970/2011). The
clinicopathological data for the analyzed sample set are
reported in Table 1.
RNA isolation, quality and quantity analyses
Total RNA including the microRNA (miRNA) fraction
was isolated with High Pure miRNA isolation kit (Cat
no: 05080576001, Roche, Penzberg, Germany) using the
one-column protocol according to the manufacturer’s
recommendation. RNA quantity was measured on a
Qubit fluorometer with the Qubit™ RNA Assay Kit (Life
Technologies, Eugene, OR, USA) and also on the
NanoDrop-1000 instrument (Thermo Fisher Scientific
Inc., Waltham, USA) to determine the purity values
(OD260/280, OD260/230). RNA quality analysis was
performed on an Agilent Bioanalyzer microcapillary
electrophoresis system with the RNA 6000 Pico Kit (Agi-
lent, Santa Clara, CA, USA).
Microarray experiment
For lncRNA expression profiling Human Transcriptome
Array 2.0 (HTA 2.0) experiments were performed with
100 ng total RNA sample input according to the manufac-
turer’s instructions. For single-stranded complementary
DNA (sscDNA) synthesis 15 μg complementary RNA
(cRNA) was used and 5.5 μg fragmented and labeled
sscDNA sample was hybridized to Human Transcriptome
Array 2.0 microarrays (Affymetrix, Santa Clara, CA, USA)
for 16 h at 45 °C with 60 rpm rotation in the Hybridization
Oven (Affymetrix). Microarrays were washed and stained
with GeneChip® Hybridization, Wash, and Stain Kit re-
agents according to the FS450_0001 protocol using the
Fluidics Station 450 instrument (Affymetrix). Scanning
was performed with GeneChip Scanner 3000 (Affymetrix).
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Table 1 Clinicopathological data of patients involved in the study
Case number # Age-range Diagnosis Adenoma grade /Astler-Coller modified Dukes stage
N1 24-76 years healthy colonic tissue
N2 healthy colonic tissue
N3 healthy colonic tissue
N4 healthy colonic tissue
N5 healthy colonic tissue
N6 healthy colonic tissue
N7 healthy colonic tissue
N8 healthy colonic tissue
N9 healthy colonic tissue
N10 healthy colonic tissue
N11 healthy colonic tissue
N12 healthy colonic tissue
N13 healthy colonic tissue
N14 healthy colonic tissue
N15 healthy colonic tissue
N16 healthy colonic tissue
N17 healthy colonic tissue
N18 healthy colonic tissue
N19 healthy colonic tissue
N20 healthy colonic tissue
Ad1 42-88 years Tubular adenoma low-grade
Ad2 Tubulovillous adenoma high-grade
Ad3 Tubulovillous adenoma low-grade
Ad4 Tubulovillous adenoma low-grade
Ad5 Tubulovillous adenoma high-grade
Ad6 Tubular adenoma low-grade
Ad7 Tubulovillous adenoma low-grade
Ad8 Villous / tubulovillous adenoma low-grade
Ad9 Tubulovillous adenoma low-grade
Ad10 Tubular adenoma low-grade
Ad11 Tubular adenoma low-grade
Ad12 Tubular adenoma low-grade
Ad13 Tubular adenoma low-grade
Ad14 Tubular adenoma low-grade
Ad15 Tubular adenoma low-grade
Ad16 Tubular adenoma low-grade
Ad17 Tubular adenoma low-grade
Ad18 Tubular adenoma low-grade
Ad19 Tubulovillous adenoma low-grade
Ad20 Tubulovillous adenoma low-grade
T1 46-87 years Colorectal adenocarcinoma Dukes C2
T2 Colorectal adenocarcinoma Dukes B2
T3 Colorectal adenocarcinoma Dukes C
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The dataset was uploaded to the Gene Expression Omni-
bus (GEO) data repository: GEO ID GSE100179. Raw
CEL file normalization was performed with the Expression
Console (Affymetrix, version: 1.4.1.46) with Gene Level –
Default: RMA algorithm in order to generate .chp files.
LncRNA expression level comparisons were made for ad-
enoma vs. healthy, CRC vs. adenoma and CRC vs. healthy
samples (FDR adjusted p < 0.05; log2FC ≤ − 1 or log2FC ≥
1). LncRNA annotation and classification (with the inclu-
sion of non-coding, 3 prime overlapping ncRNA, anti-
sense, lincRNA, sense intronic, sense overlapping and
bidirectional lncRNA subclasses of lncRNAs) were per-
formed using the BioMart data mining tool on the basis of
the current Ensembl database (Ensembl release 93 - July
2018 using GRCh38.p12 human genome version) and was
further confirmed with the Netaffx database.
qRT-PCR validation
Certain lncRNAs with significant expression alterations in
the three comparisons were further studied by qRT-PCR.
500 ng total RNA was reverse transcribed with TaqMan
MicroRNA Reverse Transcription kit (Applied Biosystems,
Foster City, CA, USA). Absolute quantification was per-
formed using LightCycler 480 Probes Mastermix (2x),
Resolight dye (40x), and primers (200 nM final concentra-
tion; Table 2.) with 5 ng cDNA/reaction with the following
thermal cycling conditions: enzyme activation: 95 °C for
10min, 45 cycles of amplification: 95 °C for 10 s, Tannealing
(CCAT1: 57 °C, LINC00261: 59 °C, UCA1: 61 °C) for 30 s
and signal detection at 72 °C for 1 s and cooling at 40 °C
for 30 s. As the normalization of expression during
lncRNA quantification is critical, absolute quantification
was performed. After PCR amplification of standard sam-
ples, amplicons were analyzed by 2% agarose gel electro-
phoresis and were purified with Agencourt AmpureXP
Beads (Beckman Coulter, Brea, USA) according to the
standard PCR purification protocol. The expression levels
of lncRNAs in the analyzed samples were quantified after
establishing standard curves with serial dilution of stand-
ard samples (with 2, 10,1 10,2 10,3 3 × 10,3 104 molecules/
reaction) calculated based on Qubit fluorometry results.
Finally, we validated the standard curves of each amplicon
and analyzed the amplification efficiency, R,2 and the
slope. LightCycler 480 absolute quantification software
was used to calculate copy numbers in the analyzed
samples.
In situ hybridization with automated RNAscope and
immunofluorescence
The in situ hybridization (ISH) analyses were performed
in collaboration with Boye Schnack Nielsen, Bioneer A/S,
Hørsholm, Denmark. Five μm thick FFPE sections were
processed for RNAscope ISH in a Ventana Discovery
Ultra instrument (Roche, Basel, Switzerland) [16]. The fol-
lowing RNAscope probes were obtained from ACD, Bio-
techne (Newark, CA, USA): UCA1 (Urothelial cancer
associated 1, NR_015379.3, target region: 659 − 2289, 20
zz pairs), dapB (a Bacillus subtilis gene, 414 – 862, 10 zz
pairs), and PPIB (Cyclophilin B, 139 – 989, 16 zz pairs),
and incubated on tissue sections as recommended by the
manufacturer. The RNAscope probes were detected using
the HRP kit and Discovery-rhodamine substrate (Roche).
Table 1 Clinicopathological data of patients involved in the study (Continued)
Case number # Age-range Diagnosis Adenoma grade /Astler-Coller modified Dukes stage
T4 Colorectal adenocarcinoma Dukes B2
T5 Colorectal adenocarcinoma Dukes D
T6 Colorectal adenocarcinoma Dukes C
T7 Colorectal adenocarcinoma Dukes B2
T8 Colorectal adenocarcinoma Dukes D
T9 Colorectal adenocarcinoma Dukes D
T10 Colorectal adenocarcinoma Dukes B2
T11 Colorectal adenocarcinoma Dukes C
T12 Colorectal adenocarcinoma Dukes B1
T13 Colorectal adenocarcinoma Dukes D
T14 Colorectal adenocarcinoma Dukes D
T15 Colorectal adenocarcinoma unknown
T16 Colorectal adenocarcinoma Dukes B2
T17 Colorectal adenocarcinoma Dukes B2
T18 Colorectal adenocarcinoma Dukes B1
T19 Colorectal adenocarcinoma Dukes B1
T20 Colorectal adenocarcinoma Dukes C
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For cytokeratin immunofluorescence, the AE1/3 mouse
monoclonal antibody (Dako-Agilent, Glostrup, Denmark)
was used at 1:200 and detected with Alexa-488 conjugated
anti-mouse Ig (Jackson Immunoresearch, West Grove,
PA). The stained sections were mounted with a DAPI-
containing anti-fade solution, ProLong Gold (Thermo
Fisher Scientific, Waltham, MA, USA). Digital whole
slides were obtained with a Pannoramic Confocal (3DHIS-
TECH Ltd., Budapest, Hungary) slide scanner using a 40x
objective, and the localization of expression was examined
in these, as well as representative images were acquired
from these digital slides.
In silico validation
lncRNA expression on an independent HTA 2.0 dataset
Our HTA 2.0 results were compared with the results of
Condorelli et al. from GEO database (GSE73360) [17] of
37 CRC biopsies from 27 patients, and 19 adjacent nor-
mal mucosa biopsies (at distance of 3-6 cm from the
tumor) that were collected directly after surgical resec-
tion. Linear correlation was analyzed between the two
datasets.
lncRNA expression on HGU133Plus 2.0 dataset
For in silico validation, expression levels of lncRNAs
were also analyzed on GSE37364 HGU133Plus 2.0
microarray (Affymetrix) dataset of 65 human colonic bi-
opsy samples (27 CRCs and 38 normal donors without
evidence of disease) [18]. Alignment of the probesets of
the different platforms was performed using the BioMart
data mining tool based on the current Ensembl database
(Ensembl release 93 - July 2018 using GRCh38.p12 hu-
man genome version). Among the significant lncRNA
expression alterations identified on HTA 2.0 arrays, 11
associated probesets could be found on the HGU133-
Plus2.0 arrays representing 10 lncRNAs. Linear correl-
ation between the two microarray platforms was also
analyzed.
lncRNA expression on TCGA dataset
Selected lncRNAs showing altered expression on HTA
2.0 arrays were analyzed in silico using The Cancer Gen-
ome Atlas (TCGA) colon & rectum adenocarcinoma
gene expression RNAseq dataset. We have used the
COAD (n = 463) subset of the lncRNA dataset from Yan
et al. which was compiled from 5.037 human tumor
specimens across 13 cancer types in TCGA [19, 20]. Out
of the 37 lncRNAs identified in our cohort showing sig-
nificant under- or overexpression in the CRC vs. N com-
parison, 16 could be detected in TCGA data. Linear
correlation was analyzed between the datasets.
LncRNA-mRNA-miRNA co-expression analysis
The HTA 2.0 microarray provides expression data of
lncRNAs and mRNAs allowing the parallel analysis of
both from individual samples. In order to assess lncRNA/
mRNA relationships, co-expression networks were con-
structed based on Pearson-correlation calculation. The
top 50 negatively and top 50 positively associated, pre-
dicted mRNA targets of the significantly (p < 0.05) altered,
qRT-PCR validated lncRNAs (UCA1 [TC19000279.hg.1,
TC19002012.hg.1] and CCAT1 [TC08001627.hg.1]) were
selected. These lncRNAs were visualized with the associ-
ated mRNAs by using igraph in the R environment and
Gene Ontology (GO) functional analysis was performed
using Netaffx database (Affymetrix). On the other hand,
MIRCODE, lncBase v2 predicted and lncBase v2 experi-
mental algorithms were used to predict miRNAs associ-
ated with UCA1 lncRNA. The expression of selected
miRNAs was analyzed on the miRNA 3.0 microarray
(GSE83924) dataset from Nagy et al. [21]. The miRWALK
database was used for miRNA-mRNA target prediction
involving 12 existing miRNA-target prediction algorithms
(DIANA-microTv4.0, DIANA-microT-CDS, miRanda-
rel2010, mirBridge, miRDB4.0, miRmap, miRNAMap,
doRiNA, PicTar2, PITA, RNA22v2, RNAhybrid2.1 and
Targetscan6.2) and containing experimentally verified data
from existing resources (miRTarBase, PhenomiR, miR2Di-
sease and HMDD) [22].
Immunohistochemistry
6 μm thick slides cut from tissue microarray (TMA)
blocks of normal (n = 20), adenoma (n = 20) and CRC
(n = 20) patients were deparaffinized and rehydrated. Anti-
gen retrieval was performed in TRIS-EDTA buffer (pH
9.0) using a microwave oven (900W for 10min, 340W
for 40min). Samples were incubated with anti-c-Met anti-
body (rabbit polyclonal, ab4193, Abcam, Cambridge, UK)
diluted 1:800 for 60min at 37 °C. EnVision + HRP system
(Labeled Polymer Anti-Mouse, K4001, Dako) and
diaminobenzidine-hydrogen peroxidase–chromogen sub-
strate system (Cytomation Liquid DAB + Substrate
Chromogen System, K3468, Dako) were applied followed
by hematoxylin counterstaining. Slides were digitally
Table 2 Primer sequences of qRT-PCR validation
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scanned using the Pannoramic 250 Flash instrument (soft-
ware version 1.11.25.0, 3DHISTECH Ltd., Budapest,
Hungary), and analyzed with a Pannoramic Viewer (v.
1.11.43.0. 3DHISTECH Ltd.) digital microscope based on
Q-score method; scored by multiplying the percentage of
positive cells (P) by the intensity (I: + 3 (strong), + 2 (mod-
erate), + 1 (weak), 0 (no staining)). Formula: Q = P x I;
maximum= 300) as described earlier [23].
Statistical analysis
For data distribution analysis the Kolmogorov-Smirnov
test was applied. Due to the normal distribution, Stu-
dent’s t-test was applied for the pairwise comparison
with Bonferroni and Hochberg correction. FDR adjusted
p-values lower than 0.05 were considered as significant.
Pearson-correlation was calculated and lncRNA-mRNA-
miRNA co-expression network was constructed by
igraph package in the R environment.
Results
Expression of known CRC-associated lncRNAs in the
colorectal adenoma and carcinoma samples
As the expression of known CRC-associated lncRNAs has
not been studied yet in precancerous adenoma samples, in
the present study we aimed to analyze the adenoma-
specific alterations with a special focus on adenoma-
carcinoma transition.
Previous comprehensive studies analyzing healthy
colon and CRC tissue samples revealed differentially
expressed lncRNAs, so-called CRC-associated lncRNA
markers [24–26]. First, the expression of these
literature-based lncRNA markers was studied on aden-
oma and CRC samples as part of our whole transcrip-
tome analysis. A subset of lncRNAs from our Human
Transcriptome Array 2.0 study (CCAT1, PVT1,
CRNDE; LINC01021, LINC-ROR, UCA1, FTX, MEG3,
LOC100289019) showed remarkable expression
changes already in the precancerous colonic lesions
(p < 0.01) (Fig. 1).
Differentially expressed lncRNAs in the colorectal
adenoma-carcinoma sequence progression
On the basis of the HTA 2.0 results, 54 lncRNAs were
found to be differentially expressed along the colorectal
adenoma-carcinoma sequence (FDR adjusted p-value<
0.05, log2FC ≥ 1 or log2FC ≤ − 1) (Additional file 1: Figure
S1, Additional file 2: Table S1). In order to focus on the
lncRNA marker candidates, whose dysregulation might be
driver in the development of CRC, a group of 17 lncRNAs
was identified as overlapping between adenoma vs. normal
and CRC vs. normal comparisons showing differential
expression early that persisted until CRC formation:
LINC02023, MEG8, AC092834.1, AL365361.1,
LINC02441, B3GALT5-AS1, THRB-IT1, LINC02535,
AC140658.1, AC142086.4, AC019330.1 and LINC01133
were downregulated and CCAT1, CASC19, LINC02163,
AC123023.1 and AC021218.1 were upregulated in aden-
oma and also in CRC samples compared to the healthy
controls (FDR adjusted p < 0.05, log2FC ≤ − 1 or log2FC ≥
1). Three lncRNAs (downregulated LINC01752, and over-
expressed UCA1 and PCAT1) were detected in both CRC
vs. N and CRC vs. Ad comparisons, suggesting that these
changes might be early markers of colonic carcinogenesis
(Fig. 2, Table 3).
The group of transcripts with altered expression only in
Ad vs. N comparison contained 2 downregulated (XIST,
PP7080) and 9 upregulated lncRNAs (top 5 with the high-
est logFC: AC124067.4, LINC01594, DLGAP1-AS2,
LINC00261. AL365226.2) (Fig. 2a, Additional file 1: Figure
S1/A, Additional file 2: Table S1). Further along the
adenoma-carcinoma sequence, lncRNAs with altered ex-
pression between CRC and adenoma samples can play a
role in the transition of dysplasia-carcinoma that
contained 8 downregulated lncRNAs (top 5 with the
lowest log2FC AL133370.1, LINC00261, AC005833.1,
LINC01612, LINC01594) (Fig. 2a, Additional file 1: Figure
S1/B, Additional file 2: Table S1). Among the lncRNAs
showing significant expression alteration exclusively in the
CRC vs. N comparison, 12 downregulated (top 5 with the
lowest log2FC: SNHG14, MIR3936HG, AC124312.3,
AL928768.1, AL359397.1) and 5 significantly upregulated
lncRNAs (AL645939.4, AC126365.1, LINC00152,
AC016831.1, LINC02474) were detected (Fig. 2a, Add-
itional file 1: Figure S1/C, Additional file 2: Table S1).
Absolute quantification
By the use of absolute quantification, we were able to
confirm the lncRNA expression alterations observed by
HTA 2.0 analyses. CCAT1 and UCA1 showed upregula-
tion in tumor samples compared to normal tissues
(Fig. 3a). In the case of LINC00261, we observed upregu-
lation in adenomas compared to normal controls and
downregulation in CRC samples compared to adenomas,
but these expression alterations were not significant
(data not shown).
In situ hybridization
In normal colonic FFPE tissue samples, no UCA1 ISH
signal was detected, whereas UCA1 ISH signal was
observed in adenoma tissue and an even stronger signal
was detected in colorectal carcinoma samples, in accord-
ance with our qRT-PCR results. The UCA1 ISH signal
was localized predominantly in the epithelial cells in
adenoma and carcinoma tissue samples (Fig. 3b).
In silico validation on an independent HTA 2.0 dataset
Our HTA 2.0 results were compared with an independ-
ent HTA 2.0 dataset [17]. The significantly altered
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lncRNA set in the CRC vs. normal comparison showed
the same tendency, a high positive correlation was found
with the independent GSE73360 dataset in the CRC vs.
NAT comparison (R2 = 0.7076) (Fig. 4a, Additional file 3:
Table S2).
In silico validation on an independent HGU133Plus2.0
microarray dataset
In order to assess the observed altered lncRNA expression
using independent hybridization-based results, HTA 2.0 re-
sults were compared for lncRNAs available on the
HGU133Plus2.0 microarray platform (GSE37364) [18]. Ac-
cording to the above-mentioned analysis, the expression al-
terations of 3 significantly upregulated (UCA1, LINC00152,
AC016831.1) and 7 downregulated (LINC02023, THRB-
IT1, LINC02535, SNHG14, AC124312.3, AL928768.1,
CDKN2B-AS1) lncRNAs were verified in CRCs compared
to the healthy controls (p < 0.01). The expression differ-
ences between the HTA 2.0 and HGU133Plus2.0 platforms
showed a high positive correlation (R2 = 0.7628) (Fig. 4b,
Additional file 3: Table S2).
In silico validation on TCGA COAD RNASeq dataset
Out of the 37 lncRNAs identified in our cohort showing
significantly differential expression in the CRC vs. N
comparison, 16 were detected on the TCGA COAD
dataset [19]. A very high positive correlation (R2 =
0.9029) was observed between the datasets (Fig. 4c, Add-
itional file 3: Table S2).
Co-expression analysis of differentially expressed
lncRNAs-mRNAs-miRNAs
mRNAs negatively correlated with CCAT1 are involved in
G1/S transition of mitotic cell cycle, G2/M transition of
mitotic cell cycle functions, while the positively correlated
mRNAs play a role e.g. in cell division and cell cycle regu-
lation. The negatively co-expressed mRNAs with UCA1
have a negative regulatory role of transcription from RNA
polymerase II promoter, angiogenesis, DNA methylation,
while the positively correlated mRNAs are involved in mi-
totic cytokinesis and apoptotic processes. The co-
expression network of lncRNAs and mRNAs showed cer-
tain overlap between the mRNA targets of the selected
lncRNAs (Fig. 5 , Additional file 4: Table S3).
UCA1 was upregulated in adenoma and also in CRC
samples (Fig. 6a) and a potential interaction was pre-
dicted between UCA1 and hsa-miR-1 based on inde-
pendent algorithms. In the GSE83924 dataset [21] hsa-
miR-1 was downregulated in adenoma and CRC samples
compared to normal colonic samples (p < 0.01) (Fig. 6b).
MIRWALK validated target prediction revealed that c-
Met mRNA is one of the targets of hsa-miR-1. On the
other hand, co-expression analysis showed that c-Met
was among the most positively co-expressed mRNAs
with both IDs of UCA1 (TC19002012: rho = 0.7811;
TC19000279.hg.1: rho = 0.7717).
Immunohistochemistry
In normal epithelium the c-Met expression was mild, dif-
fuse and cytoplasmic (main scoring value: + 1; Q-score:
144.00 ± 49.29). Compared to normal samples, adenoma
Fig. 1 CRC-associated lncRNA expression in colorectal adenoma and in CRC samples. Intensity values on the color scale were as follows: red –
high intensity, black – intermediate intensity, green – low intensity. A subset of literature-based colorectal cancer-associated lncRNAs showed
significant expression difference already between normal and adenoma samples (p < 0.01)
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samples showed elevated, but not significantly increased
(p = 0.31) epithelial protein expression (scoring values: + 1
and + 2, Q-score: 160.00 ± 29.51). In the epithelial com-
partment of CRC cases, heterogeneous, moderate/strong
(scoring values: + 2 and + 3, Q-score: 201.66 ± 43.02) c-Met
protein expression was observed which was significantly
higher than in healthy controls (p < 0.05) (Fig. 6c, d).
Discussion
The present study aimed to identify differentially
expressed lncRNAs at the whole genome level character-
istic of colorectal adenoma and carcinoma tissue
samples principally focusing on the adenoma-carcinoma
transition. Besides the detection of single lncRNA alter-
ations (by PCR-based methods, Northern blot, RNA-
immunoprecipitation and in situ hybridization [27]),
genome-wide analysis can be achieved by RNA-Seq [28]
and also by microarrays, e.g. by Human Transcriptome
Array 2.0, a high-resolution microarray platform detect-
ing lncRNA, miRNA and mRNA levels in parallel from
the same sample [29].
Certain lncRNAs were previously analyzed in colorectal
diseases, but the focus of most of the studies was limited
to one or a small set of lncRNAs [30–32]. The strength of
Fig. 2 A) Venn-diagram of the significantly altered lncRNAs in Ad vs. N, CRC vs. N and CRC vs. Ad comparisons (FDR adjusted p-value< 0.05;
log2FC≤ −1 or log2FC≥ 1). Boxplot representation of the overlapping lncRNAs showing differential expression in B) CRC vs. N and CRC vs. Ad
and C) Ad vs. N and CRC vs. N comparisons
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our study was the inclusion of colorectal adenoma tissue
samples along with the CRC cases in a genome-wide
lncRNA expression analysis, in order to identify markers
for the early detection of colorectal tumors. Based on the
present study, 54 lncRNAs were found to be differentially
expressed along the colorectal adenoma-carcinoma se-
quence that could be validated on independent microarray
results and also on TCGA COAD dataset. A subset of
lncRNAs already associated with CRC development
showed remarkable expression changes in the precancer-
ous colonic adenoma lesions.
The lncRNAs that play a key role during the malignant
transformation in CRC development remain to be iden-
tified, and therefore, we further focused on the
colorectal-adenoma transition. According to our micro-
array analysis, 12 lncRNAs were downregulated and 5
were upregulated both in adenoma and CRC samples
compared to the healthy controls. These lncRNAs might
have a key regulatory role during CRC formation, as
their dysregulation could be detected already in aden-
omas, that persisted until the malignant transition.
Among these possible key factors, CASC19 overexpres-
sion was reported in CRC tissue samples and it was as-
sociated with metastasis formation [33]; its knockdown
resulted in reduced migration of RKO and Caco2 cells
[33]. Upregulation of LINC02163 was also observed in
CRC tissue samples by NGS technology [34]. In rectal
adenocarcinoma cases Zhang et al. found an association
between LINC02163 expression and overall survival [35].
LINC02163 overexpression was documented in gastric
cancer tissues and cell lines; knockdown of LINC02163
resulted in reduced cell growth and invasion [36].
Table 3 lncRNAs with potential key role in the colorectal adenoma-carcinoma transition
Overlapping lncRNAs in the CRC vs. N & Ad vs. N comparisons
HTA 2.0 ID Annotation lncRNA name log2FC (Ad vs. N) log2FC (CRC vs. N)
TC03003192.hg.1 LINC02023 Long intergenic non-protein coding RNA 2023 -2.387** -2.960***
TC03001968.hg.1 LINC02023 Long intergenic non-protein coding RNA 2023 -2.284** -2.886***
TC14000678.hg.1 MEG8 Maternally expressed 8 -1.982** -1.028*
TC04000172.hg.1 AC092834.1 unnamed -1.610*** -1.711**
TC04001939.hg.1 AC092834.1 unnamed -1.546*** -1.664**
TC01005699.hg.1 AL365361.1 unnamed -1.318* -1.558**
TC12002119.hg.1 LINC02441 (CRAT8) Long intergenic non-protein coding RNA 2441 (cervical
cancer-associated transcript 8)
-1.315** -1.166*
TC21000464.hg.1 B3GALT5-AS1 B3GALT5 antisense RNA 1 -1.304* -1.171*
TC12003163.hg.1 LINC02441 (CRAT8) Long intergenic non-protein coding RNA 2441 (cervical
cancer-associated transcript 8)
-1.273** -1.099**
TC03001242.hg.1 THRB-IT1 THRB intronic transcript 1 -1.150** -1.326***
TC01005698.hg.1 AL365361.1 unnamed -1.122** -1.240**
TC06003749.hg.1 LINC02535 Long intergenic non-protein coding RNA 2535 -1.066* -1.192*
TC16000386.hg.1 AC140658.1 / AC142086.4 unnamed -1.061* -1.553*
TC02002653.hg.1 AC019330.1 unnamed -1.056** -1.379***
TC01001358.hg.1 LINC01133 Long intergenic non-protein coding RNA 1133 -1.000** -1.033*
TC08001627.hg.1 CCAT1 / CASC19 Colon cancer associated transcript 1 3.260*** 2.837**
TC08001626.hg.1 CASC19 Cancer susceptibility 19 2.002*** 1.607*
TC05000500.hg.1 LINC02163 Long intergenic non-protein coding RNA 2163 1.460* 1.014*
TC03000170.hg.1 AC123023.1 unnamed 1.145* 1.803*
TC07001045.hg.1 AC021218.1 unnamed 1.127** 1.086**
Overlapping lncRNAs in the CRC vs. N & CRC vs. Ad comparisons
HTA 2.0 ID Annotation lncRNA name log2FC (Ad vs. N) log2FC (CRC vs. N)
TC20000085.hg.1 LINC01752 Long intergenic non-protein coding RNA 1752 -1.117** -1.091*
TC19002012.hg.1 UCA1 Urothelial cancer associated 1 1.167* 2.048*
TC19000279.hg.1 UCA1 Urothelial cancer associated 1 1.080* 1.976*
TC08000748.hg.1 PCAT1 Prostate cancer associated transcript 1 1.006* 1.251*
*p < 0.05; **p < 0.01; ***p < 0.001
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Upregulation of AC021218.2 (CRCAL-1) was detected in
3 pairs of CRC compared to their matched normal mu-
cosa by RNA sequencing [37]. According to the current
literature in this subset, AL365226.2, LINC02023,
AC092834.1, LINC02441, B3GALT5-AS1, THRB-IT1,
LINC02535, AC140658.1, and AC142086 have not been
reported to be associated with CRC formation and these
may serve as novel lncRNA markers of neoplastic pro-
cesses of the colon.
As in the case of certain presumably ‘driver’
lncRNAs (e.g. MEG8) in the present study, a distinct
expression tendency could be detected in adenoma
and carcinoma samples, so that their dysregulation
may not be a gradual event during cancer formation.
It is well-known that up- or downregulation of
lncRNAs can be restricted to a certain stage during
cancer formation and therefore it is not evident that
all differentially expressed RNAs show the same ex-
pression tendency in adenoma and carcinoma samples
[21]. It is known, that lncRNAs show cell-specific ex-
pression in certain tumors [38] and the overall result-
ant expression found in biopsy samples can be
Fig. 3 qRT-PCR and ISH analyses of selected lncRNAs. A) UCA1 and CCAT1 qRT-PCR absolute quantification on healthy normal (n = 20), adenoma
(n = 20) and CRC (n = 20) biopsy samples *p < 0.05: UCA1: Ad vs. N, CCAT1: Ad vs. N, CRC vs. N; B) Representative UCA1 in situ hybridization
results on normal (a-d), adenoma (e-h) and CRC (i-l) FFPE tissue samples. UCA1 expression is seen already in adenoma (full arrowhead) compared
to monolayered normal adjacent (NAT) mucosa with no ISH signal (empty arrowhead) (m, n) and UCA1 is focally abundant in CRC (j). White
signals represent autofluorescence in blood cells and vessels. Digital microscope slides were scanned with Pannoramic 250 Flash instrument
(v1.11.25.0), and analyzed with a Pannoramic Viewer (v1.11.43.0) samples, scale bar: 100 μm (a-m) and 40 μm (n)
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Fig. 4 In silico validation of HTA 2.0 data on independent datasets. A) Linear correlation with an independent HTA 2.0 GEO dataset (GSE73360)
[16] [LINC02023, AC092834.1, SNHG14, AL365361.1, AC140658.1, AC142086.4, AC019330.1, THRB-IT1, LINC02535, B3GALT5-AS1, LINC02441,
MIR3936HG, AC124312.3, AL928768.1, AL359397.2, LINC01752, AL355922.2, AC087379.1, AC011891.1, AC044802.2, LINC01133, MEG8, CDKN2B-AS1,
AC025423.4, LINC01268, CCAT1, UCA1, AC123023.1, CASC19, AL645939.4, AC126365.1, LINC00152, AC016831.1, AC021218.1, LINC02474, PCAT1,
LINC02163], B) Linear correlation with an independent HGU133 Plus 2.0 dataset (GSE37364) [17] [UCA1, LINC00152, AC016831.1 LINC02023, THRB-
IT1, LINC02535, SNHG14, AC124312.3, AL928768.1, CDKN2B-AS1] C) Linear correlation with TCGA COAD dataset [18] [LINC01133, AL365361.1,
LINC00152, LINC02023, LINC02163, LINC01268, CASC19, CDKN2B-AS1, AC087379.1, LINC02441, SNHG14, AC124312.3, UCA1, LINC01752, CCAT1,
AL928768.1]. Our own HTA 2.0 data (GSE100179) are represented on X-axis
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influenced by the epithelial-stromal cell ratio which
may differ between colorectal adenomas and adeno-
carcinomas. On the other hand, similarly to the find-
ings on miRNA [21] and on DNA methylation levels
[39], certain lncRNAs showed distinct expression al-
terations in adenomas and carcinomas that might be
due to the counteracting cell-proliferation control
pathways in adenomas that are dysregulated in
carcinomas.
LncRNAs characteristic only in the malignant state could
be identified in the intersection of CRC vs. N and CRC vs.
Ad comparisons, where significant downregulation of
LINC01752 and overexpression of PCAT1 and UCA1 were
observed. Although the altered expression of these
lncRNAs are hypothetically associated with malignancy in
colonic tumors, due to the relatively low number of CRCs
analyzed in the present study, no reliable further conclusion
can be formed about the correlation of their expression
Fig. 5 Co-expression network of lncRNAs with associated mRNAs. qPCR validated lncRNAs (UCA1 [TC19000279.hg.1, TC19002012.hg.1], CCAT1
[TC08001627.hg.1]) are represented with orange rectangles, target mRNAs are represented with green rectangles in the network, where further
associations between the mRNA targets are also represented. The network was visualized with igraph in R environment and Gene Ontology (GO)
functional analysis was performed using TAC 4.0 software (Affymetrix)
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levels with survival, metastasis or tumor stage data in our
cohort. However, on the basis of literature data, overexpres-
sion of PCAT1 was suggested to be an independent prog-
nostic factor for CRC [40] and its downregulation inhibited
proliferation, blocked cell cycle transition, suppressed cyclin
and c-myc expression and induced apoptosis [41]. Silencing
of PCAT1 in Caco− 2 and HT-29 cell lines suppressed cell
motility, invasiveness, sensitized the cells to 5-FU [42]. Hu-
man urothelial carcinoma associated 1 (UCA1) lncRNA has
a role in cell proliferation, apoptosis, and cell cycle progres-
sion regulation and an increased UCA1 expression level
was reported first in urothelial cancer [43] and also re-
ported for breast cancer and CRC patients [44–46]. Ac-
cording to Ni et al., CRC patients with high UCA1
expression had a poor prognosis and UCA1 overexpression
was found to be an independent predictor of CRC [47]. Ex-
ogenous expression of UCA1 enhanced tumorigenicity, in-
vasive potential, and drug resistance in human bladder
TCC BLS-211 cells [43]. Silencing of UCA1 in HCT116,
HT29, SW480 and LoVo cell lines significantly decreased
cell proliferation, while UCA1 overexpression promoted
tumorigenicity in LoVo cells [48]. Silencing of UCA1 sup-
pressed proliferation and metastasis and induced apoptosis
of oral squamous cell carcinoma cell lines, which may be
related to the activation of the WNT/β-catenin signaling
pathway [49]. In a recent study, UCA1 expression was also
detected in liquid biopsy samples, where Tao et al. reported
that the elevated expression level in the tissue samples can
Fig. 6 A) UCA-1 lncRNA expression in healthy colon, colorectal adenoma, and CRC tissue samples; B) hsa-miR-1 expression on GSE83924 miRNA
3.0 array dataset [20] C) C-Met expression quantification and D) C-Met protein levels in the epithelial compartments of normal colon (D/1),
adenoma (D/2) and CRC samples (D/3). Digital microscope slides were scanned with Pannoramic 250 Flash instrument (v1.11.25.0), and analyzed
with a Pannoramic Viewer (v1.11.43.0), 40x magnification, scale bar: 50 μm) Box plots represent the median and standard deviation of the
data (*p < 0.05)
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also be detected in plasma samples of CRC patients [50].
The above-mentioned functions of UCA1 illustrate the
complexity of its mechanism of actions and its diverse role
in CRC development [51].
To date, there has been no data reported about UCA1
expression in colorectal adenoma patients. According to
our results, UCA1 shows a gradual upregulation in the
normal-adenoma-cancer sequence, thus besides its well-
established malignancy-associated functions, it holds the
possibility to be utilized as an early detection marker for
precancerous lesions of the colon, that may contribute to
reduce CRC-related deaths in the future.
Interestingly, a slight discrepancy was observed in
UCA1 expression between microarray and qRT-PCR
methods. By the two probe sets on HTA 2.0 microarray
representing UCA1, all 36 transcripts can be detected,
while in contrast, qRT-PCR primers used in the present
study detect 4 transcripts (namely UCA1-213, UCA1-207,
UCA1-201, and UCA1-228). The above-mentioned reason
probably contribute to the discrepant expression results
observed between the two platforms. Nevertheless, in situ
hybridization probes could detect all UCA1 transcripts,
and as an added advantage, this approach also provide in-
formation regarding lncRNA subcellular localization in
colonic tissue samples. Tripathi et al. recently reported
moderate UCA1 expression using ISH on colorectal can-
cer tissue [52]. To the best of our knowledge, our study is
the first to report evidence of the upregulation of UCA1
lncRNA in colorectal adenomas and cancers predomin-
antly observed in the epithelial cells adding additional evi-
dence for UCA1 overexpression along colorectal cancer
formation.
UCA1 has been reported to regulate miRNAs, such as
miR-216b and hsa-miR-1 as a miRNA sponge and as a
ceRNA of miR-204-5p among others, influencing growth
promotion, apoptosis inhibition and 5-FU resistance [48,
53, 54]. The mutual inhibitory effect and the inverse ex-
pression of UCA1 and hsa-miR-1 have already been
proven in bladder cancer and one functional interaction
site was experimentally confirmed between hsa-miR-1
and UCA1 [54]. Furthermore, after the transfection of
pre-miR-1 or following the treatment of UCA1 shRNA,
cell proliferation and motility decreased in bladder can-
cer cell lines in an AGO2-mediated manner [54]. Down-
regulation of miR-1 in tumors compared to the
corresponding normal tissue samples is associated with
worse prognosis and its lower expression has been re-
ported to reprogram cancer metabolism via the regula-
tion of tumor glycolysis in colorectal cancer [55]. The
interaction between hsa-miR-1 and HGFR (c-Met) is
well-known in CRC [56]. On the basis of the compre-
hensive microarray analysis of Nagy et al. [21] and our
present results, the downregulation of hsa-miR − 1 along
the adenoma-carcinoma sequence was accompanied by c-
MET overexpression. Upregulated UCA1 might exert its
effect on c-Met protein and therefore can be associated
with metastasis formation and CRC progression. Continu-
ous overexpression of c-Met protein was observed along
with the development of CRC [57, 58], which could be
confirmed in our cohort, as well. On the basis of our co-
expression analysis, c-Met was among the most positively
co-expressed mRNAs of UCA1. Taken together, the asso-
ciation of UCA1, hsa-miR-1 and c-Met was predicted by
independent algorithms in our study. However, further
functional experimental verification is needed to prove the
hypothetized interactions in CRC.
Besides the studies aiming at the identification of a
signature marker group of lncRNA candidates differen-
tially expressed between CRC and normal samples either
on the basis of tissue or plasma samples (e.g. circulating
XLOC_006844, LOC152578 and XLOC_000303) [59] or
between high-risk and low-risk CRC patients with differ-
ent overall survival [60], our study identified a subset of
lncRNAs potentially playing a key role during the
adenoma-carcinoma transition complementing the
present knowledge about CRC formation.
Conclusion
In summary, the defined lncRNA sets may have a regu-
latory role in the adenoma-carcinoma transition. A sub-
set of lncRNAs showed significant differential expression
already in precancerous samples that persisted until
CRC formation, raising the possibility of developing
adenoma-specific markers in order to achieve early de-
tection of colonic lesions.
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